Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer

Clinical Lung Cancer

Volumn 18, Issue 2, 2017, Pages 189-197.e3

  Menter, Alex R ^a   Carroll, Nikki M ^a   Sakoda, Lori C ^b   Delate, Thomas ^a   Hornbrook, Mark C ^c   Jain, Rakesh K ^d   Kushi, Lawrence H ^b,e   Quinn, Virginia P ^a   Ritzwoller, Debra P ^a  

^a KAISER PERMANENTE   (United States)

^b DIVISION OF RESEARCH   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin; Bevacizumab; Chemotherapy; Microenvironment; Non small cell lung cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; ADVANCED NON SMALL CELL LUNG CANCER; AGED; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; DEATH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; NONSQUAMOUS NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; RETROSPECTIVE STUDY; CANCER GRADING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; PACLITAXEL; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84994891094     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.07.008     Document Type: Conference Paper

References (41)

1. 1 Brambilla, E., Travis, W.D., Müller-Hermelink, H., et al. (eds.) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart, 2014, World Health Organization, Geneva, Switzerland World Health Organization Classification of Tumours. Available at: http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/BB10.pdf Accessed: February 29, 2016.
2. 2 NSCLC Meta-Analyses Collaborative Group, Chemotherapy in addition to supportive care improves survival in advanced non–small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26 (2008), 4617–4625.
3. 3 Sandler, A., Gray, R., Perry, M.C., et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med 355 (2006), 2542–2550.
4. 4 Jain, R.K., Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26 (2014), 605–622.
5. 5 Kim, E.S., Lee, J.J., He, G., et al. Tissue platinum concentration and tumor response in non–small-cell lung cancer. J Clin Oncol 30 (2012), 3345–3352.
6. 6 Jain, R.K., Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31 (2013), 2205–2218.
7. 7 Minchinton, A.I., Tannock, I.F., Drug penetration in solid tumours. Nat Rev Cancer 6 (2006), 583–592.
8. 8 Stylianopoulos, T., Martin, J.D., Chauhan, V.P., et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A 109 (2012), 15101–15108.
9. 9 Chauhan, V.P., Martin, J.D., Liu, H., et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun, 4, 2013, 2516.
10. 10 Wilop, S., von Hobe, S., Crysandt, M., et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non–small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135 (2009), 1429–1435.
11. 11 Nakai, Y., Isayama, H., Ijichi, H., et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103 (2010), 1644–1648.
12. 12 Kim, S.T., Park, K.H., Oh, S.C., et al. How does inhibition of the renin–angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?. Oncology 83 (2012), 354–360.
13. 13 Keizman, D., Huang, P., Eisenberger, M.A., et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 47 (2011), 1955–1961.
14. 14 Ritzwoller, D.P., Carroll, N.M., Delate, T., et al. Patterns and predictors of first-line chemotherapy use among adults with advanced non–small cell lung cancer in the Cancer Research Network. Lung Cancer 78 (2012), 245–252.
15. 15 Ritzwoller, D.P., Carroll, N., Delate, T., et al. Validation of electronic data on chemotherapy and hormone therapy use in HMOs. Med Care 51 (2013), e67–e73.
16. 16 Ross, T.R., Ng, D.J., Brown, J.S., et al. The HMO Research Network Virtual Data Warehouse: a public data model to support collaboration. EGEMS (Wash DC), 2, 2014, 1049.
17. 17 North American Association of Central Cancer Registries. NAACCR strategic management plan, 2011-2016. Available at: http://www.naaccr.org/AboutNAACCR/SMP.aspx. Accessed: February 29, 2016.
18. 18 Delate, T., Won, K., Carroll, N., et al. Factors associated with first-line bevacizumab use in advanced non-squamous non–small cell lung cancer. J Cancer Res Ther 2 (2014), 1–8.
19. 19 Ritzwoller, D.P., Carroll, N.M., Delate, T., et al. Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the Cancer Research Network experience. J Thorac Oncol 9 (2014), 692–701.
20. 20 Delate, T., Bowles, E.J., Pardee, R., et al. Validity of eight integrated healthcare delivery organizations’ administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev 21 (2012), 637–680.
21. 21 D'Agostino, R.B. Jr., Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998), 2265–2281.
22. 22 Austin, P.C., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46 (2011), 399–424.
23. 23 Hershman, D.L., Wright, J.D., Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol 30 (2012), 4215–4222.
24. 24 Faires, D.E., Leon, A.C., Haro, J.M., et al. (eds.) Propensity Score Stratification and Regression: Analysis of Observational Health Care Data Using SAS, 2010, SAS Institute, Cary, NC, 23–46.
25. 25 Robins, J.M., Hernan, M.A., Brumback, B., Marginal structural models and causal inference in epidemiology. Epidemiology 11 (2000), 550–560.
26. 26 Kurth, T., Walker, A.M., Glynn, R.J., et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163 (2006), 262–270.
27. 27 Austin, P.C., Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28 (2009), 3083–3107.
28. 28 Austin, P.C., Mamdani, M.M., A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 25 (2006), 2084–2106.
29. 29 Austin, P.C., The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33 (2014), 1242–1258.
30. 30 Sperry, S.M., Charlton, M.E., Pagedar, N.A., Association of sentinel lymph node biopsy with survival for head and neck melanoma: survival analysis using the SEER database. JAMA Otolaryngol Head Neck Surg 140 (2014), 1101–1109.
31. 31 Cox, D.R., Partial likelihood. Biometrika 62 (1975), 269–276.
32. 32 Kumar V, Boucher Y, Liu H, et al. Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma. Transl Oncol, in press.
33. 33 Ramalingam, S.S., Dahlberg, S.E., Langer, C.J., et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26 (2008), 60–65.
34. 34 Zhu, J., Sharma, D.B., Gray, S.W., et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non–small cell lung cancer. JAMA 307 (2012), 1593–1601.
35. 35 Dahlberg, S.E., Schiller, J.H., Bonomi, P.B., et al. Body mass index and its association with clinical outcomes for advanced non–small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol 8 (2013), 1121–1127.
36. 36 Bosco, J.L., Silliman, R.A., Thwin, S.S., et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol 63 (2010), 64–74.
37. 37 Hoang, T., Dahlberg, S.E., Sandler, A.B., et al. Prognostic models to predict survival in non–small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 7 (2012), 1361–1368.
38. 38 Lin, J.J., Gallagher, E.J., Sigel, K., et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med 191 (2015), 448–454.
39. 39 Saxena, A., Becker, D., Preeshagul, I., et al. Therapeutic effects of repurposed therapies in non–small cell lung cancer: what is old is new again. Oncologist 20 (2015), 934–945.
40. 40 Medairos, R.A., Clark, J., Holoubek, S., et al. Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non–small cell lung cancer. J Thorac Cardiocasc Surg 152 (2016), 55–61.
41. 41 Wink, K.C., Belderbos, J.S., Dieleman, E.M., et al. Improved progression free survival for patients with diabetes and locally advanced non–small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiother Oncol 118 (2016), 453–459.